Skip to content
  • Sunday, 26 July 2026
  • 1:41 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Eli Lilly Commits Up to $3.8 Billion to Acquire AtaiBeckley, Betting on the ‘God Molecule’ 5-MeO-DMT for Transformative Mental Healthcare
Laboratory Automation & Robotics

Eli Lilly Commits Up to $3.8 Billion to Acquire AtaiBeckley, Betting on the ‘God Molecule’ 5-MeO-DMT for Transformative Mental Healthcare

Lana Keisha Jul 24, 2026 0

Indianapolis, IN – Pharmaceutical giant Eli Lilly has announced a definitive agreement to acquire AtaiBeckley, a clinical-stage biotechnology company focused…

Read More
Pharmaceutical R&D

Eli Lilly Acquires AtaiBeckley for $2.8 Billion, Marking Entry into Psychedelic Therapeutics

Teuku Ryan Jul 20, 2026 0

In a landmark move that signals a significant shift in pharmaceutical investment, Eli Lilly and Company has announced the acquisition…

Read More
Laboratory Automation & Robotics

Lilly offers up to $3.8 billion for AtaiBeckley in bet on ‘God molecule’ found in toad venom

Lana Keisha Jul 16, 2026 0

Eli Lilly has formally agreed to acquire AtaiBeckley for a substantial sum, comprising $2.8 billion upfront and an additional $1…

Read More
Emerging therapies bring hope for frail HNSCC patients unfit for standard treatment – Pharmaceutical TechnologyA GLP-1 bone study shows why matching matters in real-world evidenceTWiV 1288: Clinical Update with Dr. Daniel Griffin Discusses Alarming Shifts in Childhood Immunization Schedules and Persistent Public Health ThreatsHuman Skeletal Development Blueprint Reveals New Insights into Arthritis and Congenital Bone Conditions
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ